ewsba.se
Written by Robert Izquierdo for The Motley Fool->
COO Julie Rubinstein sold 19,037 shares for a transaction value of ~$271,000 on April 27, 2026, at a weighted average price of around $14.23 per share.
This trade represented 4.8% of her direct holdings at the time, reducing her direct position from 396,839 to 377,802 shares.
The transaction was executed directly and involved the exercise of 14,707 options with no indirect entity participation.
Julie Rubinstein, President and Chief Operating Officer of Adaptive Biotechnologies Corporation (NASDAQ:ADPT), reported the exercise of 14,707 options and immediate sale of 19,037 shares of common stock on April 27, 2026 for a total value of approximately $271,000, as disclosed in the SEC Form 4 filing.
Transaction and post-transaction values based on SEC Form 4 weighted average purchase price ($14.23).
Adaptive Biotechnologies Corporation is a biotechnology company specializing in immune-driven diagnostics and therapeutic platforms, with a market presence in both research and clinical settings.
The company leverages proprietary immunosequencing technology and strategic partnerships to address unmet needs in disease diagnosis and monitoring. Its integrated approach and collaborations with industry leaders position it as a key innovator in immune medicine.
The April 27 sale of Adaptive Biotechnologies stock by Chief Operating Officer Julie Rubinstein is not a red flag for investors. She executed the transaction as part of her Rule 10b5-1 trading plan adopted in November of 2025. Such plans are often implemented by executives to avoid accusations of making trades based on insider information.
In addition, Rubinstein maintained a significant equity stake in the company. Post-transaction, she had 377,802 directly-held shares along with 45,731 stock options. This suggests she is not rushing to dispose of her holdings.
Adaptive Biotechnologies stock went on a run in 2025, reaching a 52-week high of $20.76 last November, but has since pulled back. The drop in share price makes sense since it had reached a lofty valuation, as evidenced by a price-to-sales ratio exceeding 12 last year.
Adaptive Biotechnologies exited 2025 with sales of $277 million, representing a strong 55% increase over the prior year. It had an operating loss of $57.1 million in 2025, but that’s a significant reduction from 2024’s loss of $162.5 million. However, the company expects a modest increase in operating costs in 2026.
With the stock price’s drop, now may be an opportunity to buy shares, if you believe the company can continue to grow sales while keeping its costs under control.
Before you buy stock in Adaptive Biotechnologies, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Adaptive Biotechnologies wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $496,473!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,216,605!*
Now, it’s worth noting Stock Advisor’s total average return is 968% — a market-crushing outperformance compared to 202% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of May 4, 2026.
Robert Izquierdo has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
This data feed is not available at this time.